GlassScriptPhysician profile
John C Crosby
NPI 1891783072
$4,615.96
in general payments reported to CMS, 2019-2025
31 companies · $540 in 2025
The $540 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,558 · 2020: $644 · 2021: $471 · 2022: $171 · 2023: $376 · 2024: $856 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,771.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,639.63 | 2019-2025 | Proclaim, Eterna |
| Collegium Pharmaceutical, INC. | $688.73 | 2019-2025 | Belbuca, Xtampza, Nucynta |
| Scilex Pharmaceuticals INC. | $335.39 | 2019-2025 | Ztlido |
| Boston Scientific Corporation | $308.47 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $280.30 | 2020-2025 | Relistor, Trulance |
| Valinor Pharma, LLC | $274.67 | 2024-2025 | Movantik |
| Si-Bone, INC. | $149.78 | 2019-2024 | |
| Nevro Corp. | $122.53 | 2019 | |
| Biodelivery Sciences International, INC. | $85.39 | 2019-2021 | |
| Forte Bio-Pharma LLC | $82.72 | 2020-2024 | Prolate, Nalocet |
| Bioventus LLC | $58.86 | 2019-2025 | Durolane |
| Lifeward, INC. | $52.26 | 2024 | |
| Ossur Americas, INC. | $49.00 | 2025 | Unloader One X |
| Zyla Life Sciences, INC. | $42.14 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $41.66 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $41.24 | 2025 | Evoke |
| Pacira Therapeutics, INC. | $41.02 | 2021 | |
| Redhill Biopharma INC. | $38.38 | 2020-2021 | |
| Medtronic USA, INC. | $35.60 | 2019 | |
| Nalu Medical, INC. | $31.57 | 2021-2024 | Nalu Neurostimulation System |
| Kaleo, INC. | $28.94 | 2019 | |
| Azurity Pharmaceuticals, INC. | $24.88 | 2024 | Horizant |
| Horizon Therapeutics Plc | $24.77 | 2021 | |
| Globus Medical, INC. | $24.17 | 2025 | Senza |
| Vertex Pharmaceuticals Incorporated | $23.15 | 2025 | |
| Averitas Pharma INC. | $21.29 | 2025 | Qutenza |
| Daiichi Sankyo INC. | $16.06 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.94 | 2019 | |
| Assertio Therapeutics, INC. | $14.11 | 2020 | |
| Sentynl Therapeutics, INC. | $12.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Crosby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.